StreetInsider.com News Articles

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $76 at Citi

Thu, 16 Jul 2026 05:03:43 -0400

Citi analyst Eric Joseph raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $76.00 (from $75.00) while maintaining a Buy rating.

H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)

Tue, 14 Jul 2026 06:57:58 -0400

H.C. Wainwright analyst Mitchell Kapoor reiterated a Neutral rating and $50.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).

The analyst commented: "Yesterday, BioMarin announced that the FDA had accepted the company's supplemental New Drug Application (sNDA) for VOXZOGO (vosoritide) for full approval in children with achondroplasia (ACH). The agency has set a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027. If approved, VOXZOGO would be the first therapy for ACH to convert from accelerated approval to traditional approval based on a comprehensive clinical data package, including adult height outcomes and other clinical measures evaluated over

BioMarin completes acquisition of Amicus Therapeutics

Mon, 13 Jul 2026 16:15:01 -0400

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has completed its acquisition of Amicus Therapeutics, Inc., according to a filing with the U.S. Securities and Exchange Commission.

BioMarin filed a Current Report on Form 8-K on April 27, 2026, disclosing the consummation of the deal. Under the terms of the merger agreement, dated December 19, 2025, Amicus became a wholly owned subsidiary of BioMarin through a merger involving Lynx Merger Sub 1, Inc., a wholly owned subsidiary of BioMarin.

Both BioMarin and Amicus are incorporated in Delaware.

BioMarin completes acquisition of Amicus Therapeutics

Mon, 13 Jul 2026 16:15:01 -0400

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has completed its acquisition of Amicus Therapeutics, Inc., according to a filing with the U.S. Securities and Exchange Commission.

Both BioMarin and Amicus are incorporated in Delaware.

Form 8-K/A BIOMARIN PHARMACEUTICAL For: Apr 27

Mon, 13 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260713/26762519.html

Form 8-K/A BIOMARIN PHARMACEUTICAL For: Apr 27

Mon, 13 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260713/26762519.html

FDA accepts BioMarin's application for full approval of achondroplasia drug

Mon, 13 Jul 2026 09:05:29 -0400

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the U.S. Food and Drug Administration has accepted the company's supplemental New Drug Application for full approval of Voxzogo (vosoritide) in children with achondroplasia. The FDA set a Prescription Drug User Fee Act target action date of Feb. 28, 2027.

Voxzogo received FDA accelerated approval in 2021 based on measures reasonably likely to predict clinical benefit. The supplemental application is intended to fulfill a postmarketing requirement to confirm that benefit and convert the drug to traditional approval status.

The submission is supported by long-term safety and efficacy data from three ongoing studies, including outcomes related

FDA accepts BioMarin's application for full approval of achondroplasia drug

Mon, 13 Jul 2026 09:05:29 -0400

The submission is supported by long-term safety and efficacy data from three ongoing studies, including outcomes related

FDA accepts BioMarin's application for full approval of achondroplasia drug

Mon, 13 Jul 2026 09:05:29 -0400

The submission is supported by long-term safety and efficacy data from three ongoing studies, including outcomes related

FDA accepts BioMarin's application for full approval of achondroplasia drug

Mon, 13 Jul 2026 09:05:29 -0400

The submission is supported by long-term safety and efficacy data from three ongoing studies, including outcomes related

FDA accepts BioMarin's application for full approval of achondroplasia drug

Mon, 13 Jul 2026 09:05:29 -0400

The submission is supported by long-term safety and efficacy data from three ongoing studies, including outcomes related

FDA accepts BioMarin's application for full approval of achondroplasia drug

Mon, 13 Jul 2026 09:05:29 -0400

The submission is supported by long-term safety and efficacy data from three ongoing studies, including outcomes related

U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia

Mon, 13 Jul 2026 09:05:00 -0400

Application based on long-term safety and efficacy data from three ongoing studies, including adult height and additional clinical outcomes beyond linear growth, including body proportionality and arm span evaluated over long-term follow-up